Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 ≥ 100 cells/mm 3

Journal of the Medical Association of Thailand

Volumn 89, Issue 9, 2006, Pages 1381-1387

  Kiertiburanakul, Sasisopin ^a   Sungkanuparph, Somnuek ^a   Rattanasiri, Sasivimol ^a   Manosuthi, Weerawat ^b   Vibhagool, Asda ^a   Thakkinstian, Ammarin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

AIDS; CD4; Efavirenz; Highly active antiretroviral therapy; HIV

Indexed keywords

DIDANOSINE; EFAVIRENZ; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXAZINES; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 33749440046     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-4.
3. Friedl AC, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, et al. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 2001; 15: 1793-800.
4. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-73.
5. Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, et al. Efavirenz-based regimen as treatment of advanced AIDS with cryptococcal meningitis. J Acquir Immune Defic Syndr 2003; 33: 118-9.
6. Kebba A, Atwine A, Mwebaze R, Kityo C, Nakityo R, Peter M. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. AIDS Res Hum Retroviruses 2002;18:1181-7.
7. The EfaVIP Cohort Study Group. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 Study). J Acquir Immune Defic Syndr 2004; 35: 343-50.
8. Ruxrungtham K, Phanuphak P. Update on HIV/AIDS in Thailand. J Med Assoc Thai 2001; 84: S1-17.
9. Sathapatayavongs B, Thakkinstian A, Promchanyakul K. Five-year experience on AIDS 1990-94: Ramathibodi Hospital, Thailand. J Infect Dis Antimicrob Agents 1999; 16: 69-72.
10. StataCorp. Stata Statistical Software, Release 8.0. College Station, TX, Stata Corporation, 2003.
11. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.
12. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). April 7, 2005. Available at http://AIDSinfo.nih.gov, assess April 30, 2005.
13. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4: 1-41.
14. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA 2004; 292: 251-65.
15. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286: 2560-7.
16. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286: 2568-77.
17. Lepri AC, Miller V, Phillips AN, Rabenau H, Sabin CA, Staszewski S. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. AIDS 2001; 15: 47-54.
18. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002; 3: 279-86.
19. Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34: 838-46.
20. Datta D, Moyle G, Mandalia S, Gazzard B. Matched case-control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy. HIV Med 2003;4:311-4.
21. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 447-54.